Paula Green Sells 910 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 910 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $33,788.30. Following the completion of the transaction, the senior vice president now owns 91,511 shares in the company, valued at approximately $3,397,803.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total transaction of $7,497.46.
• On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The shares were sold at an average price of $33.52, for a total value of $6,704.00.
• On Wednesday, March 6th, Paula Green sold 600 shares of Twist Bioscience stock. The stock was sold at an average price of $37.43, for a total value of $22,458.00.

Twist Bioscience Price Performance

Shares of TWST traded down $1.54 during trading hours on Tuesday, hitting $43.13. The stock had a trading volume of 1,808,210 shares, compared to its average volume of 997,886. Twist Bioscience Co. has a 52 week low of $11.81 and a 52 week high of $44.92. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -12.84 and a beta of 1.64. The company’s fifty day moving average is $34.11 and its two-hundred day moving average is $31.34.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company’s revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) earnings per share. Equities analysts predict that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Institutional Trading of Twist Bioscience

Large investors have recently made changes to their positions in the business. Federated Hermes Inc. bought a new position in shares of Twist Bioscience in the third quarter valued at about $29,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after acquiring an additional 721 shares during the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience during the fourth quarter worth approximately $30,000. Allspring Global Investments Holdings LLC grew its stake in shares of Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after purchasing an additional 3,907 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TWST. Barclays lifted their price objective on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday. Robert W. Baird lifted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday. Scotiabank increased their price objective on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Finally, Evercore ISI upped their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience has an average rating of “Buy” and a consensus target price of $42.50.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.